Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: SNGX (MC $50 M) Covid 19 Vac / 3x Phase 3 Drugs =MEGA OPP

No earlier versions found for this Subject.

Return to SNGX (MC $50 M) Covid 19 Vac / 3x Phase 3 Drugs =MEGA OPP

CHEAPEST Covid 19 Vaccine gem ....

Low valuation of 49 million --has 3x Phase 3 programs with Data in Q4 / and a Covid 19 Vaccine programm with data coming soon ..has potential to move like INO or NVAX ...

Soligenix (SNGX)

Marekt Cap $50 Million
Price: $1.89

Shares Out 26. 6 M

Presentation
ir.soligenix.com

Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis

finance.yahoo.com

Final top-line results expected Q4 2020

SNGX: Q&A on COVID-19 Vaccine Candidate CiVax™…
finance.yahoo.com

As a reminder, following the positive topline data presented by the company for SGX-301 in CTCL, we continue to anticipate Phase 3 data for SGX-942 in oral mucositis in the fourth quarter of 2020. The company will also be joining the Russell Microcap Index effective June 29th, 2020, which should help to increase visibility within the investment community. Our current valuation is $12 per share.